Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + PD-1 antibody + short-course chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
ChiCTR2100051738Phase 2Not yet recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Anhui Cancer Hospital. Primary endpoint: Quality of life score. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
trastuzumabsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ChiCTR2100051738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051738.